Nordic Nanovector's plan to emerge from its current troubles by merging with APIM Therapeutics has hit an insurmountable hurdle – in the shape of its own shareholders.
Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics.<
Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started a restructuring process and called in investment bank Carnegie to help explore